Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.

ABSTRACT:

Introduction

Trialists need a thorough understanding of whether reactions to Alzheimer's disease (AD) biomarker information differ among racial and ethnic groups in preclinical AD trials.

Methods

We used data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study to analyze cognitively unimpaired participants' responses on the Impact of Event Scale (IES) 24 to 72 hours after amyloid disclosure. We fit a linear regression model to test whether mean IES scores differed among participants from specific racial and ethnic groups. We considered potential effect modification by amyloid status.

Results

Reactions to disclosure did not significantly differ among participant groups based on self-reported race and ethnicity. Although the results were not signif

SUBMITTER: Ritchie M 

PROVIDER: S-EPMC11032552 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature